Skip to main navigation Skip to search Skip to main content

Excretion profile of 4-methylthioamphetamine in dogs

  • P. V. Kavanagh
  • , D. Corrigan
  • , R. T. Maguire
  • , M. J. Meegan
  • , J. J. Keating
  • , J. Clancy
  • , J. Burdett

Research output: Contribution to journalArticlepeer-review

Abstract

4-Methylthioamphetamine (4-MTA) is a new drug of abuse, and owing to a number of deaths in the EU over a 2-year period, it has become a major cause for concern. Little is known about the metabolism, half-life or excretion profile of 4-MTA, in man. We used a canine model to study the excretion profile of 4-MTA. Urine samples were screened for 4-MTA with EMIT amphetamine immunoassay, followed by confirmatory analysis using GC-MS. 4-MTA was detectable using EMIT-amphetamine immunoassay down to 1 μgmL-1 in drug- free urine samples to which 4-MTA was added. 4-MTA was detectable by EMIT up to 23 h after administration. Base extracted urine samples were subjected to flash derivatization using N methylbis(trifluoroacetamide) and the resulting trifluoroacetylated compound yielded a well fragmented mass spectrum under the GC-MS conditions used. Quantification of 4-MTA in the urine samples revealed 15, 11 and 20 μg mL-1 at 5.5, 13.5 and 23h, respectively. 4-MTA is detectable by immunoassay at 1 μg mL-1 and can be detected in dogs up to 23 h after administration. EMIT positive screens can be checked using GC- MS incorporating derivatization to confirm the presence of 4-MTA.

Original languageEnglish
Pages (from-to)653-655
Number of pages3
JournalPharmacy and Pharmacology Communications
Volume5
Issue number11
DOIs
Publication statusPublished - Nov 1999
Externally publishedYes

Fingerprint

Dive into the research topics of 'Excretion profile of 4-methylthioamphetamine in dogs'. Together they form a unique fingerprint.

Cite this